OneDigital Investment Advisors LLC Reduces Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

OneDigital Investment Advisors LLC trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 590 shares of the company’s stock after selling 227 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in IDEXX Laboratories were worth $298,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Chicago Partners Investment Group LLC lifted its holdings in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after acquiring an additional 96 shares during the last quarter. Manning & Napier Advisors LLC purchased a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $20,418,000. Oppenheimer Asset Management Inc. grew its stake in shares of IDEXX Laboratories by 13.8% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock valued at $5,825,000 after buying an additional 1,453 shares during the last quarter. National Pension Service raised its holdings in shares of IDEXX Laboratories by 7.3% in the third quarter. National Pension Service now owns 185,972 shares of the company’s stock worth $93,957,000 after buying an additional 12,647 shares during the period. Finally, EFG Asset Management Americas Corp. raised its holdings in shares of IDEXX Laboratories by 45.3% in the second quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company’s stock worth $6,201,000 after buying an additional 3,966 shares during the period. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IDXX. Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Barclays reduced their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. JPMorgan Chase & Co. lowered their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. BTIG Research began coverage on IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective on the stock. Finally, Stifel Nicolaus lowered their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Stock Up 0.2 %

Shares of NASDAQ:IDXX opened at $419.37 on Friday. The firm has a market capitalization of $34.34 billion, a PE ratio of 40.44, a price-to-earnings-growth ratio of 3.63 and a beta of 1.36. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The firm’s 50-day moving average is $462.53 and its two-hundred day moving average is $481.11.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same period in the previous year, the firm posted $2.53 EPS. IDEXX Laboratories’s revenue for the quarter was up 6.6% on a year-over-year basis. Analysts predict that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.